Kate Zhang is Vice President, Biological Development for Editas Medicine. Kate joined Editas Medicine in September 2018 and is responsible for leading translational science and early- and late-stage biological development for the Company.
Prior to joining Editas Medicine, Kate spent more than 20 years at Genzyme/Sanofi with multiple roles of increasing responsibilities. At Genzyme, she participated and led multiple functional teams in Protein and Cell Therapeutic Development to support Biologics License Application (BLA) approval and commercialization of multiple biologics, including Cerezyme, Fabrazyme, Myozyme/Lumizyme for Gaucher, Fabry and Pompe diseases, respectively. Beginning in 2006, she served as the global science lead for diagnosis, screening and monitoring of lysosomal storage diseases. Later at Sanofi, Kate served as portfolio head of global translational science responsible for rare disease therapeutic area. She also served as science liaison to Genzyme/Sanofi business units on rare nephrology and hematology. Kate has authored and co-authored more than 70 publications on peer-reviewed high impact journals, two book chapters, and four patents.
Kate earned a B. Eng from Tsinghua University in Beijing, China; a M.Sc. from the Chinese Academy of Science; and a Ph.D. in Analytical Chemistry/Biochemistry at Queen’s University, Ontario, Canada. She completed her postdoctoral fellowship at National Heart, Lung and Blood Institute, NIH, Bethesda, MD.
